Design, optimization and validation of compounds against cancer-Initiating cells.

• Unité de recherche: INNOSUISSE
• Numéro de projet: 12985.1;6 PFLS-LS
• Titre du projet anglais: Design, optimization and validation of compounds against cancer-Initiating cells.

Description succincte (Allemand)

Design, optimization and validation of compounds against cancer-Initiating cells.

Description succincte (Anglais)

Design, optimization and validation of compounds against cancer-Initiating cells.

Résumé des résultats (Abstract) (Allemand)

This CTI project aims at identifying a preclinical candidate and generate a selection of back-up compounds to treat brain cancer, in order to accelerate and improve the development programs of Stemergie Biotechnology SA. The combination of the unique technology expertise of Stemergie in cancer-initiating cells with the medicinal chemistry technologies and know-how of the Carreira Group at the ETH Zurich shall enable the development of novel drug candidates to treat brain cancer patients.

Résumé des résultats (Abstract) (Anglais)

This CTI project aims at identifying a preclinical candidate and generate a selection of back-up compounds to treat brain cancer, in order to accelerate and improve the development programs of Stemergie Biotechnology SA. The combination of the unique technology expertise of Stemergie in cancer-initiating cells with the medicinal chemistry technologies and know-how of the Carreira Group at the ETH Zurich shall enable the development of novel drug candidates to treat brain cancer patients.